View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML
DOJ/DEA RIN: 1117-AA62 Publication ID: Spring 2004 
Title: Security Requirements for Handlers of Pseudoephedrine, Ephedrine, and Phenylpropanolamine 
Abstract: DEA is proposing to require that manufacturers, distributors, importers, and exporters of pseudoephedrine, ephedrine, and phenylpropanolamine implement security procedures similar to those of Schedules III through V controlled substances to prevent the theft and diversion of these List I chemicals. Pseudoephedrine and ephedrine are used in the illegal manufacture of methamphetamine, and phenylpropanolamine is used in the illegal manufacture of amphetamine. The vast majority of these clandestine laboratories were producing methamphetamine using over-the-counter regulated drug products. Some of the product found at these clandestine laboratories came from thefts at manufacturers, distributors, importers, and exporters. Almost all of the reports of List I chemical thefts reported to DEA in the past few years have involved pseudoephedrine, ephedrine, or phenylpropanolamine. Therefore, to address the problem of diversion of pseudoephedrine, ephedrine, and phenylpropanolamine through theft, DEA is proposing that manufacturers, distributors, importers, and exporters of these three chemicals implement security procedures similar to those now used by registrants handling Schedules III through V controlled substances. These procedures include the storage of substances in a secure safe or steel cabinet, cage, or room and installation of a monitored alarm system linked to a central location. DEA will also be seeking input regarding alternative means to effectively prevent the theft and diversion of these products. Keeping pseudoephedrine, ephedrine, and phenylpropanolamine products in such secure areas will limit the opportunity for theft. 
Agency: Department of Justice(DOJ)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Proposed Rule Stage 
Major: No  Unfunded Mandates: No 
CFR Citation: 21 CFR 1309   
Legal Authority: 21 USC 821    21 USC 822    21 USC 823    21 USC 824    21 USC 830   
Legal Deadline:  None
Timetable:
Action Date FR Cite
NPRM  06/00/2004    
NPRM Comment Period End  08/00/2004    
Additional Information: DEA-211
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Small Entities Affected: No  Federalism: No 
Included in the Regulatory Plan: No 
Agency Contact:
Patricia M. Good
Chief, Liaison and Policy Section
Department of Justice
Drug Enforcement Administration
Office of Diversion Control,
Washington, DC 20537
Phone:202 307-7297